there are several great immunotherapy trials ongoing in Canada (you can put "Canada" in the search box of the Clinical trial Finder for MSS-CRC in my signature, curated by Tom (our DK37 fellow, on this forum). BUTT I wanted to point out three that are "only in Canada" and specially important. (Two of them are not on the curated spreadsheet/ app).
Clinical trial, for LIVER mCRC
*Only Toronto, Canada.
*LIVE DONOR LIVER TRANSPLANTATION for the treatment of unresectable colorectal cancer liver metastases
A radical treatment, which has as antecedent the Oslo trial.
"This study will offer live donor liver transplantation (LDLT) to select patients with unresectable metastases that are 1) limited to the liver and 2) stable (non-progressing) on standard chemotherapy. Potential participants will be evaluated for liver transplant suitability and must also have a willing, healthy living donor come forward for evaluation.
***********MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours (I214) https://clinicaltrials.gov/ct2/show/NCT02285816
The Phase I admits CRC, supposedly, if the tumour test positive for what they are looking for.
: Janet Dancey 6135336430 firstname.lastname@example.org Locations
Canada, British Columbia
BCCA - Vancouver Cancer Centre Recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Contact: Daniel John Renouf 604 877-6000
Juravinski Cancer Centre at Hamilton Health Sciences Recruiting
Hamilton, Ontario, Canada, L8V 5C2
Contact: Sebastien Hotte 905 387-9495
Ottawa Hospital Research Institute Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Derek Jonker 613 737-7700
University Health Network Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Albiruni R A Razak 416 946-4501
Sponsors and Collaborators
Canadian Cancer Trials Group
Ottawa Hospital Research Institute
*******************Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
Only in TO, Princess Margaret Hospital
*Similar* to the TIL trial at NHI (our Sleen / Celine trial
One needs to check if tumour qualifies.
Histologically or cytologically confirmed metastatic or recurrent unresectable solid tumor.HLA-A*02:01 or HLA-A*02:06 positive.Tumor NY-ESO-1 expression by immunohistochemistry.
No anti-cancer chemotherapy, radiation therapy or immunotherapy within 2 weeks of PBMC harvest.
If approved and funded standard therapy is available, subjects must have failed, be intolerant to, be ineligible for, or have refused treatment.
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension
(longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >10 mm with CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease. Patients must have radiographic evidence of disease progression following the most recent line of treatment. Areas of previous radiation may not serve as measurable disease unless there is evidence of progression post radiation.ECOG Performance Status 0 or 1.
"The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer and malignant melanoma. Patients must be positive for HLA-A*02:01 or HLA-A*02:06 and the patient's tumor tissue must be positive for NY-ESO-1 antigen expression. The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells.
The manufacturing of T cells takes about 1 month to complete. The T cells will be given back to the subject through an intravenous infusion.
The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with advanced solid tumors."Contacts
Marcus Butler, MD 416-946-4521 email@example.com
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Marcus Butler, M.D. 416-946-4521 firstname.lastname@example.org
Principal Investigator: Marcus Butler, M.D.